Home / Transcripts / Arcutis Biotherapeutics, Inc. (ARQT) · August 5, 2026

Arcutis Biotherapeutics, Inc. (ARQT) Earnings Call Transcript

August 5, 2026

NASDAQ US Health Care Biotechnology earnings 67 min

Earnings Call Speaker Segments

Brian Schoelkopf executive
#1

Thanks, Michelle. Hi, everyone, and thanks for being with us this afternoon as we go over the financial results for our second quarter of 2026 along with a business update. You can find the slides for today's call in the Investors section on the Arcutis website. With me today are Frank Watanabe, our President and CEO of Arcutis, Patrick Burnett, our Chief Medical Officer, and Latha Vairavan, our Chief Financial Officer. I want to remind all of you that forward-looking statements will be made during this call. Such statements carry certain risks and uncertainties, and our actual results could differ. We urge you to review all of the company's filings with the Securities and Exchange Commission, which include descriptions of our business and risk factors. So with that, I'll turn things over to Frank to kick off today's call.

Frank Watanabe executive
#2

Thank you, Brian, and hello everyone on this call this afternoon. We're grateful, as we always are, that all of you took the time to be with us for this quarterly update. This afternoon I'll begin by going over what was a highly productive second quarter, during which we kept bringing meaningful innovation to patients dealing with chronic inflammatory skin diseases and kept carrying out our grow, expand, build corporate strategy. Todd could not be with us today, so I'll take you through the commercial portion, then Patrick will cover R&D, and after that Latha will go over the financial results for the quarter, and then we'll take your questions. I'm looking at slide five of the deck. As a reminder, our strategy rests on three pillars aimed at sustaining growth both near term and long term: first, growing our core ZORYVE business within the indications we already have approved. Second, moving into further indications where ZORYVE's distinctive profile as a targeted and potent PDE4 inhibitor holds considerable promise for filling persistent therapeutic gaps. Third, using our deep clinical expertise and infrastructure to build our pipeline beyond ZORYVE. I'm pleased to say that once again, we achieved substantial progress on all three pillars in the second quarter. Let's begin with the grow pillar. Our in-line ZORYVE business keeps getting stronger and keeps growing as we broaden the reach and relevance of this medicine for the tens of millions of people in the U.S. living with chronic inflammatory skin conditions, who need and deserve new, innovative therapeutic options for managing their plaque psoriasis, severe dermatitis, and atopic dermatitis. With ZORYVE still growing, we're now able to put the significant capital it generates back into the business, forming a virtuous cycle of innovation that brings our transformative impact to more patients, both through ZORYVE and through current and potential future pipeline assets. As we'll talk about today, our investment in innovation spans a broad range of value-creating initiatives across the business that we're advancing in parallel, from multiple clinical projects to impactful patient access initiatives. On a few of the highlights: at the close of June, we obtained FDA approval for ZORYVE cream 0.3% to treat plaque psoriasis in children as young as age 2. That represents the seventh FDA approval for ZORYVE in 4 years, a remarkable accomplishment for a small company like Arcutis. Importantly, this milestone lets us address a significant treatment gap, bringing forward the first once-daily steroid-free treatment for plaque psoriasis approved down to age 2. In July, the FDA also accepted our supplemental NDA for ZORYVE cream 0.05% to treat mild to moderate atopic dermatitis in infants down to 3 months, with a PDUFA date set for February 23, 2027. I was recently at the Society for Pediatric Dermatology, and frankly, the level of anticipation and excitement in the pediatric dermatology community about this potential approval left me awestruck, since it would address an urgent unmet need for a once-daily nonsteroidal option in these youngest of AD sufferers. Each of these regulatory achievements shows how dedicated we are to bringing real innovation to adults and kids in every age bracket, even the youngest patients dealing with these chronic inflammatory skin conditions, along with the people who care for them. Later today you'll learn more about how our dedication to meaningful innovation for patients extends past launching new therapies; we understand that living with a chronic inflammatory skin disease such as psoriasis, atopic dermatitis, or seborrheic dermatitis can be incredibly difficult and heavy for patients and their families. Because of that, we're applying our expertise toward finding ways to innovate that improve the patient experience and make access to treatment seamless, so we can help lighten the load for patients, caregivers, and healthcare providers alike. Today we'll walk through a few of our patient access initiatives that are designed specifically to lower obstacles to care and make the patient journey smoother. Our new virtual health platform, together with our strategic partnership involving a leading AI-enabled patient access support tool, represent the first results to come out of our wider patient access initiative innovation workstream; these efforts have us genuinely excited, and I'll go into more detail on them soon. Both illustrate well how committed we are to delivering meaningful innovation to patients. Moving to growing our second strategic pillar, we keep making significant strides this quarter when it comes to assessing what ZORYVE might do in other chronic inflammatory skin conditions. To be specific, the phase II proof of concept trial of ZORYVE for treating vitiligo is now completely enrolled, and enrollment continues for the phase II proof of concept trials of ZORYVE as a therapy for hidradenitis suppurativa. During earlier calls, we described the broad and expanding set of conditions for which clinicians have published case reports or case series revealing encouraging signs of ZORYVE efficacy, which hints that ZORYVE's distinctive profile as a targeted, potent PDE4 inhibitor might give more patients an innovative non-steroidal treatment choice. We keep assessing these other possible indications and expect to launch one or more further proof of concept trials during this year. Last, moving to the third pillar, build. We keep making headway in moving our innovative pipeline forward. Enrollment is underway for the phase I-A, phase I-B trial of ARQ-234, our novel biologic aimed at CD200R as a possible therapy for moderate to severe atopic dermatitis. Since CD200R plays a central part in both innate and adaptive immunity, targeting it leads us to believe ARQ-234 might serve not just as a significant first-line systemic therapy, but could also tackle the obvious and separate need for a treatment for atopic dermatitis patients who have relapsed on IL-4/13 drugs or who are refractory to them. Beyond that, as we've mentioned before, external innovation will probably be central to growing our pipeline. Recently we've observed a notable rise in deal flow across dermatology and nearby inflammation areas. Our team stays actively involved in assessing a variety of external assets as we work to build out our pipeline. As Latha is going to walk through, financially we delivered yet another exceptionally strong quarter. The performance we're seeing at this level, along with the cash flow it throws off, lets us keep putting money into innovation while remaining faithful to our biotech heritage and our mission. Through the rest of this year, what you should anticipate is steady execution on the strategy we've laid out, reinvesting in the business when opportunities arise, and an unwavering dedication to building long-term value for patients as well as shareholders. Given how well our ZORYVE business has done so far, and considering the added investments we're making to keep demand for ZORYVE going, we're pleased to lift our full year 2026 sales guidance from the earlier range of $480 million-$495 million up to a range of $525 million-$540 million. You'll remember that on our Q1 earnings call we left our revenue guidance untouched. Revising it each quarter isn't something we plan to do, and this guidance truly captures the momentum the business has experienced across the first half of the year. Let me now go a bit deeper into a few specifics regarding commercial results for the quarter. I'm on slide seven at this point. In the second quarter we keep seeing strong sales results and growth driven by demand, with net product revenues reaching $129.9 million, which is a 59% rise versus the second quarter of 2025 and a 23% gain compared with Q1.

Frank Watanabe executive
#3

The sustained strength we keep seeing each quarter in revenue really highlights how much momentum the ZORYVE franchise has and how durable that strength is. Our gross net rate, as we had anticipated, showed a modest step-up versus the quarter before, and it has stayed steady within the 50s. When we look toward Q3, we're anticipating sequential net sales gains, powered by demand from patients that keeps carrying forward. Let me move on to slide 8 now. On a rolling 4-week average basis, weekly scripts for ZORYVE demonstrate ongoing expansion throughout the portfolio. We set a fresh peak for quarterly demand, exceeding 280,000 prescriptions during the quarter across every indication and formulation of ZORYVE. This chart makes clear that ZORYVE keeps delivering considerable growth in prescriptions. We expect that rising demand to persist for the rest of 2024 and further out, and it should serve as the main engine behind revenue growth for ZORYVE. The single biggest factor fueling ZORYVE's expansion will still be the shift away from topical steroids toward advanced targeted topicals such as ZORYVE, as the way providers and patients view the dangers of long-term topical steroid usage keeps changing. Let's move to slide 9 at this point. I'd like to say more about the patient access programs we rolled out during this quarter. As I mentioned at the start, making it easier for patients to get ZORYVE is a key aspect of meaningful innovation, given that our goal is to serve people living with chronic inflammatory skin conditions. Innovation in therapeutics means nothing when patients can't get hold of new treatments, so we view it as essential that we also innovate when it comes to lowering obstacles to treatment and care. It's important to note that these fresh patient access programs stand apart from our payer access work and are distinct from it, yet they work in a complementary way. These innovations target enabling smooth fulfillment plus an efficient process after the prescription is written, which helps patients obtain ZORYVE quickly, dependably, and with minimal friction; we've taken this holistic, patient-first approach to innovation ever since ZORYVE came to market, but we are now widening what our patient access efforts cover with the introduction of our virtual health platform and spending on AI-enabled tools that assist with efficient prescription fulfillment. These are 2 separate initiatives, and both are meant to make access to ZORYVE smoother. Let me share a bit more on each, beginning with the virtual health platform, which we told you about in June. We see that for the past several years, the way patients get healthcare has been shifting fast, beginning with the COVID pandemic and speeding up as many virtual health options such as Hims or Ro have appeared. A large number of people these days want care that's more convenient and flexible. Our virtual health platform acknowledges that shift and connects with patients on their own terms by helping tackle typical obstacles to dermatology care, including lengthy waits for dermatology appointments and the lack of specialized dermatology care in certain areas. For people who would otherwise put off or skip specialized dermatology treatment, the platform offers another route. It's worth stressing that the platform is built to supplement traditional in-office dermatology care, not take its place. We aim to assist a greater number of people in obtaining the treatments they require, while we keep working alongside healthcare professionals in dermatology, primary care, and pediatrics. Through Milo, independent board-certified dermatologists working on that platform assess, make diagnoses, and decide on suitable therapy for every person according to their own clinical judgment. Arcutis exerts no influence over diagnoses, clinical decision-making, or prescribing choices made via the platform. When a prescription is written, ZORYVE orders get coordinated through a national pharmacy hub built to enable a smooth experience, encompassing insurance assistance and delivery to the home. This new platform excites us in particular, since we think ZORYVE's profile fits the virtual health model perfectly. Dermatologists are able to prescribe ZORYVE with confidence because of its proven efficacy, safety, and tolerability, without concern that a patient might apply the drug to a body area where it shouldn't go, and knowing the patient may use ZORYVE for whatever duration is needed; it addresses the three most frequent inflammatory diseases, every one of which can be diagnosed visually through telehealth tools. On top of that, people afflicted by these diseases feel driven to pursue an effective therapy because of how much their symptoms weigh on them. We remain in the early stages of rolling out our virtual health platform, yet signals of the impact it will deliver are already apparent, and we are confident it will meaningfully benefit efforts to expand patient access to ZORYVE, especially when combined with our other demand generation efforts, such as the Free to Be Me campaign; in late July, we introduced our second patient access innovation, teaming up with one of the leading AI-enabled prescription workflow platforms to make the post-prescription process for ZORYVE smoother in dermatology offices. Getting any prescribed therapy to a person has become progressively more complex and time-consuming over the years. Via this partnership, we are assisting in streamlining patient access to ZORYVE once the prescription has been received. The company we have partnered with already enjoys wide adoption across dermatology offices and other therapeutic areas throughout the country. In practices where the tool has been implemented, after providers initiate a prescription, the platform helps navigate and systematize the workflow that follows; beyond that, it gives patients real-time visibility into the process starting at the moment of prescription, along with other critical information and access resources. As part of the collaboration with Arcutis, the platform delivers customized prompts and alerts to streamline the steps between a clinical decision and an individual starting ZORYVE, covering prior authorization, financial assessment, and fulfillment routing embedded directly into healthcare provider workflows; we're skating to the puck. It's our belief that harnessing innovation and leveraging these types of technology-based solutions to help patients and healthcare providers with the fulfillment process for ZORYVE is where we need to be. These programs represent significant further milestones in our pursuit of bringing impactful innovation to every aspect of dermatologic treatment; as shown on slide 10, such patient access efforts are merely the most recent illustration of how we are channeling the cash flow that ZORYVE produces back into the franchise in order to fuel durable expansion and a sales inflection in 2027 and afterward. Naturally, every one of our attempts to fuel ZORYVE's expansion would be pointless absent the strong base provided by ZORYVE's remarkable clinical profile. ZORYVE's swift and powerful effectiveness across numerous inflammatory dermatoses, combined with its extraordinary safety and tolerability profile and its formulations designed to be friendly to patients, render it an appealing option for healthcare providers and patients seeking to manage these chronic conditions, particularly given the escalating worry regarding extended use of topical steroids. Our commercial endeavors center on building awareness of this distinctive therapeutic profile among both clinicians and patients, then facilitating streamlined patient access to the product once it is determined to be the suitable therapeutic intervention. Resting on that base are three wide-ranging categories of demand initiatives. The initial one consists of the investments we are making to reinforce our commercial infrastructure via focused additions to our sales force. The expansion of the dermatology sales force is now finished, with our new dermatology specialty reps entering the field as of early May. From that point, they have been building familiarity with their customers, and as discussed previously, we expect to start seeing the effect on growth from these reps starting in the third quarter of this year.

Frank Watanabe executive
#4

Additionally, we've finished constructing the initial stage of our primary care and pediatric structure, and we've just wrapped up bringing on board the specific team we were aiming for. Our expectation is that by the close of this month, these sales representatives will be out in the field engaging with primary care physicians and pediatric specialists, and we think we'll start noticing results from this group in 2027. Just to reiterate, our strategy with this sales team is extremely focused, zeroing in on PCPs and pediatricians in large urban markets who see high volumes of patients and tend to adopt new products early. With this strategy, the money we've put into a PCP ped sales team should start delivering returns quickly. As we develop a deeper grasp of this area and the optimal ways to collaborate with primary care and pediatric clinicians, we'll consider whether to grow the team further. We think certain characteristics of ZORYVE's profile—the same ones that made it a leader in dermatology and that will fuel significant uptake via the virtual health platform—will likewise propel its success among primary care providers. To be specific, PCPs and pediatricians can feel assured prescribing ZORYVE given its proven effectiveness, safety, and tolerability, with no concerns about where or for how long patients utilize it. Our second piece of the commercial investment plan involves our direct consumer initiatives. Through our Free to Be Me patient awareness campaign—starring Tori Spelling, her daughter Stella McDermott, and pro golfer Max Homa—we're generating substantial patient engagement. This effort is boosting awareness about treatment choices for those with atopic dermatitis, seborrheic dermatitis, and plaque psoriasis, along with the potential of ZORYVE for each of these conditions. These initiatives are clearly connecting with a wide variety of patient groups, which mirrors the extensive segments of the population affected by these illnesses. Our virtual health platform makes this campaign even more powerful, since it gives people who find ZORYVE through Free to Be Me a direct path to a dermatologist. We're eager to see this crucial direct-to-consumer push keep advancing as we strive to capture and mirror how patients actually live with their chronic inflammatory skin conditions, including incorporating ZORYVE into their treatment plans. The last element of our commercial investment approach is making it easy for patients to get ZORYVE, which we've covered today. The virtual health platform and the AI-driven prescription workflow work I mentioned before represent our first steps in this direction, but more thrilling projects are on the way, and we can't wait to reveal the specifics at a later time; so with that, I'll pause and hand things over to Patrick for the R&D update.

Patrick Burnett executive
#5

Thanks, Frank. I'll pick up on slide 12. Frank set the tone at the start of this call by pointing to the three pillars of our corporate strategy — grow, expand, and build — and how we're focused on each. What I want to do now is add some color on the clinical side of those pillars. Before I walk through the individual clinical programs, let me stress how wide-ranging our efforts are right now to keep strengthening ZORYVE's profile. What you see on this chart is the set of clinical programs we're running with the goal of reaching more patients, moving into additional disease areas where early data suggest activity, and sharpening our understanding of what makes ZORYVE's therapeutic profile distinctive. The number of approved and possible uses for ZORYVE — backed by a pleiotropic mechanism of action plus its safety and tolerability — is the foundation for our conviction that ZORYVE holds a uniquely strong position to replace topical corticosteroids when treating inflammatory dermatoses. Now let me turn to the main clinical updates from the quarter. As Frank noted earlier, late in June the FDA gave the green light to our supplemental NDA, broadening the indication for ZORYVE cream 0.3% to cover topical treatment of plaque psoriasis — intertriginous areas included — in children as young as two years old. Having practiced as a dermatologist, I can say from personal experience that managing plaque psoriasis in young children comes with distinct difficulties. To be specific, safety and tolerability are always top of mind, but that worry grows even greater for young children, who could be looking at decades of treatment and who are especially vulnerable to the risks of both local and systemic steroid exposure, such as HPA suppression; in our trials involving children as young as two years of age who had plaque psoriasis, ZORYVE 0.3% showed safety, tolerability, and efficacy on par with what had already been seen in adults and adolescents. ZORYVE is now the first steroid-free, once-daily plaque psoriasis treatment cleared for patients down to age two. For healthcare providers, parents, and other caregivers, it offers an advanced targeted topical option that may be applied anywhere on the body and for any length of time, which fills a meaningful gap in care for this very young and particularly vulnerable group of patients; in July, we shared that the FDA has accepted our supplemental NDA for ZORYVE cream 0.05% to treat mild to moderate atopic dermatitis in infants as young as three months, with a PDUFA date of February 23rd, 2027. As we said on our first quarter call, we managed to file this application only three months after reading out top-line results from our INTEGUMENT infant trial. That's a remarkable achievement, and it speaks to how quickly our Arcutis team is working for patients, and to the intense urgency felt by the HCPs who look after these youngest atopic dermatitis patients. That urgency to bring forward new and better therapies stems from particular difficulties involved in treating this infant population. For the youngest kids, their skin hasn't matured completely, so there's a chance of greater systemic uptake from topicals such as steroids, and those very young patients frequently arrive with disease that's more widespread than what we see in teens and grown-ups. This quarter, we got two additional studies underway. One is in adults, designed to shed more light on how ZORYVE affects pruritus, meaning itch. That study goes by the name INTEGUMENT-Itch, and it draws on the strong results from the INTEGUMENT trial in infants, which demonstrated itch reductions starting 10 minutes after the initial application. The other will assess what ZORYVE does for nail psoriasis, a form of plaque psoriasis famous for being stubborn to treat and frequently even resistant to systemic therapy, where case reports have shown us some genuinely encouraging signs of ZORYVE working. Now shifting to possible new indications for ZORYVE: enrollment has wrapped up in our phase II proof-of-concept study in vitiligo. We're still enrolling the phase II proof-of-concept studies in hidradenitis suppurativa, or HS. We're still on schedule to deliver a readout for the vitiligo study and a decision about whether to move that program forward in quarter four of this year. For our HS program, we're likewise on track for a readout of that kind in quarter one of 2027. Keep in mind that within our HS program, we have studies assessing ZORYVE's safety and efficacy in HS, plus a study examining gene expression after ZORYVE treatment in HS patients. While we move these phase II vitiligo and HS studies ahead, we're also looking at other diseases for proof-of-concept studies along the same lines, and we expect to launch one or more further proof-of-concept studies during the back half of the year. In quarter two, we also began a study evaluating how ZORYVE cream 0.3% affects cutaneous adverse events in cancer patients undergoing PD-1 or PD-L1 checkpoint inhibitor treatment. These kinds of side effects show up in up to half of patients on these life-saving therapies, and they frequently end up interfering with cancer treatment. Should ZORYVE manage to control these treatment-related dermatoses effectively, as some case reports indicate, it could assist cancer patients in staying on their PD-1 or PD-L1 regimen; this study stands as another important illustration of the wide-ranging potential uses for ZORYVE across inflammatory skin conditions. Finally, let's discuss ARQ-234, our novel biologic aimed at CD200R and the build pillar of our strategy. As Frank Watanabe mentioned earlier today, by going after CD200R, which is central to both innate and adaptive immunity, we think ARQ-234 could tackle the substantial unmet need for a systemic therapy among patients with moderate to severe atopic dermatitis, and because of its distinctive mechanism of action, it might serve as a compelling first-line option, along with a choice for patients who are refractory to IL-4/13 therapies. Enrollment is now complete in the final cohort of healthy volunteers in the single ascending dose, or SAD, portion of the phase I study for ARQ-234. We have started enrolling patients with atopic dermatitis into the last SAD cohorts, and we are going to begin enrolling AD, or atopic dermatitis, patients in the multiple ascending dose, or MAD, part of the study. After that MAD part, we will also finish a modest proof-of-concept portion in patients with atopic dermatitis. As I said during our first quarter call, we will not disclose results from this trial before it is finished, but we will keep updating you as we move through these various parts of the study. We also keep assessing outside sources for innovation so we can further expand our innovative pipeline. As Frank Watanabe said earlier, the greater deal flow in dermatology and eye care is encouraging to us. Now let's turn to slide 13. We first showed this slide at our R&D day last fall. It sets out the many features a therapy would need in order to not just compete with topical steroids in chronic inflammatory skin disease settings, but to displace them as well. In efficacy and speed of onset, ZORYVE is arguably comparable to topical corticosteroids, yet as shown here, it then surpasses the steroid benchmark in breadth of mechanism of action, safety and tolerability, and duration and location of use, and the extent of differentiation grows more and more pronounced along each dimension. ZORYVE's distinctive profile, together with rising HCP recognition of the risks tied to sustained topical corticosteroid use, which we have reviewed thoroughly before, creates the basis not only for meaningful growth in our three in-line indications, but also for possible expansion into a number of new indications. I wanted to go over this view of ZORYVE's profile today as important context for the wide array of clinical activities we are pursuing. The scope and ambition of our clinical efforts have no equal in the branded non-steroidal topical segment and are made possible by ZORYVE's distinctive therapeutic profile; they further show why ZORYVE is uniquely positioned to displace topical corticosteroids at a time when concern is growing over the harmful side effects of prolonged or inappropriate use of these aging drugs. I will now pass it to Latha to go over the financial results for this quarter.

Latha Vairavan executive
#6

Thanks, Patrick, and good afternoon to all of you. I'm looking at slide 15. During Q2, our net product revenues came in at $129.9 million, which works out to a 59% rise over the second quarter of 2025. That year-over-year gain came mainly from higher patient demand along with better gross to net sales deductions. As we had expected, gross to net for Q2 stayed steady in the 50s. Cost of sales for Q2 totaled $10.9 million versus $7.5 million in Q2 of 2025, reflecting rising ZORYVE sales volume. In the second quarter of 2026, our R&D expenses were essentially unchanged at $20.4 million, compared with $19.5 million during the matching period in 2025, since greater spending on medical affairs initiatives and clinical expense tied to ARQ-234 was mostly offset by lower clinical costs for the INTEGUMENT infant trial in atopic dermatitis patients aged 3 to 24 months. SG&A expenses reached $82.1 million in the second quarter of 2026, versus $69.2 million a year earlier, a 19% increase, largely from personnel costs, including the expansion of our dermatology sales force. We posted net income of $15 million for the quarter, compared with a net loss of $15.9 million in the same period of 2025, as robust top-line growth kept outpacing expenses. Although we might keep producing positive net income in certain quarters, our priority as an innovative biotech is still investing to keep driving top-line growth and moving our pipeline forward. Turning to Slide 16. We closed the quarter with $238.9 million in cash and marketable securities, having generated positive cash flow from operating activities of $12.6 million during the period. We anticipate staying cash flow positive for the remainder of the year. As we've said before, we plan to keep plowing the capital we generate back into our business to inflect growth in 2027 and beyond. Our total debt stands at $101.9 million. As Frank shared at the start of today's call, we are raising our full year 2026 net revenue guidance to a range of $525 million to $540 million; this revised range accounts for the contribution from the new commercial initiatives Frank outlined today, along with the ongoing strength of our core ZORYVE business. With that, I'll hand the call back to Latha for some closing updates.

Frank Watanabe executive
#7

Okay, thank you, Latha. Today we are also sharing that Todd Edwards is going to step down from his position as Chief Commercial Officer at Arcutis, leaving to seek other opportunities for personal reasons, with that change taking effect later this month. I’d like to express my gratitude to Todd for the leadership he has shown across these past three years. He played a key part in establishing the commercial foundation that made ZORYVE’s success possible up to now, and that same foundation will keep supporting ZORYVE’s ongoing expansion. I’m also very pleased to share that Rob Lisicky will take on the role of interim Chief Commercial Officer as we run a national search to find a permanent CCO. Rob is a deeply seasoned biopharma leader whose career has covered 30 years in this industry. Most recently, Rob served as CEO at Zura Bio, and before that role, he held the position of Chief Commercial Officer at Arena Pharmaceuticals right up until Pfizer acquired it in 2022. Even earlier, he was CCO at Daiichi Sankyo USA. Rob and I have been acquainted for decades, going back to when we worked together on ENBREL, and he carries extensive experience leading top-tier commercial teams in inflammation and immunology, as well as in generating fast sales growth to create blockbuster franchises. The know-how Rob will bring to our commercial operation at Arcutis comes at just the right moment, as we move toward a stretch of sustained and accelerating sales inflection for ZORYVE in the near term. Q2 marked yet another quarter of remarkably strong execution from the Arcutis team. I feel enormous pride in this team and in the commitment they show daily to pushing our mission forward, creating value for shareholders, and staying firmly devoted to the patients we serve now and those we intend to serve going forward. In early June, Arcutis marked its 10th anniversary. What began as three guys and an idea has grown into a powerhouse biotechnology company with four FDA-approved products and a pipeline of promising programs and assets. Even more significant, across the past decade, we have assisted close to a million people in managing their chronic inflammatory disease, and we are positioned to assist millions more down the road. Reflecting on the last decade, I feel humbled by and profoundly grateful for what our team members have contributed, along with the dermatology clinicians who have worked alongside us, the patients who chose to take part in our trials, and the investors whose belief in us was strong enough that they placed their money with us. My sincere thanks to all of you; with that, I’ll turn the call over to Q&A.

Seamus Fernandez analyst
#8

Oh, excellent. I appreciate you taking the questions. I'd like to begin — that bump to guidance is certainly impressive. Frank, I hear you on not anticipating quarterly revisions to the outlook. When it comes to how things are trending as we move through the second half, what would you call the primary growth engines right now? It genuinely seems as though the foam is beginning to really distinguish itself. Sales of the 0.05% are off to a solid start as well. I was hoping to get a clearer picture of how you view the growth path for the remainder of this year, and where additional opportunities might emerge from the access you're creating through telehealth; that telehealth possibility looks like it could be fairly significant, though I imagine we're all curious about what the eventual price points will be there. Turning to Todd stepping down, I believe the 8-K indicated that he's leaving Arcutis for a different opportunity. The team appears to be very solidly assembled at this stage. The strategy has delivered results, and you're moving to an interim leader with an impressive background. What's occupying most of your attention specifically throughout this transition?

Frank Watanabe executive
#9

Yes. Seamus, I appreciate the questions. I'll take the first one. Honestly, we keep observing expansion throughout the portfolio. As you noted, the foam is our top product. It's a genuinely distinctive, highly differentiated asset. It's the sole nonsteroidal in a foam form. For physicians, it's essentially the only foam they can get. Obtaining topical foams has become quite difficult nowadays. I believe physicians and patients have had a very positive response to it. We're seeing growth everywhere. As you pointed out, the 0.05 continues to expand quite well. I think that reflects the unmet need for effective nonsteroidals among younger children, and it also signals the potential of 0.05 for those aged three to 24 months, assuming we receive approval in February as anticipated; we'd anticipate ongoing portfolio-wide growth during the second half, mostly fueled by rising demand. There could be slight incremental gains in gross net, though I wouldn't anticipate anything major considering how strong our gross nets already are at this stage of the year. As the year moves along, I think we'll begin to see the effects of various initiatives we've discussed today. The dermatology expansion, I believe, will take hold in the latter half of the year. Primary care is likely too soon, but I expect that in 2027. Regarding telehealth, my sense is that most of these patients will be able to get ZORYVE covered by their insurance; we've arranged with the platform so patients can take that path. Unlike certain alternatives available now, where patients must cover the cost of the medication on their own — think GLP-1s, for instance — this works differently. With this, it's as though the patient were visiting a physician's office. A physician evaluates the patient, selects a treatment, and should they pick ZORYVE — and picking ZORYVE isn't mandatory, though it's an excellent option across all 3 of these conditions — should they pick ZORYVE, that instantly places them into a workflow where the PA gets completed, the insurance company covers the ZORYVE, and we send it out to the patient. What ZORYVE costs the patient is identical to what it would be at a dermatologist's office. Let me think. Finally, on the subject of the transition. Todd assembled an exceptionally solid commercial leadership group. In just the past 6 months, I believe, we've brought in Katherine Swolfs to head up the primary care initiative. She's performing remarkably well. We recruited Chris Kloc away from AbbVie to head the sales team. Our commercial team is genuinely strong. I have zero concern about them steering our commercial results through this transition. Rob's start date precedes Todd's exit, ensuring a smooth handoff between the 2 of them. Honestly, I can't imagine anyone better suited to join us and assist, not just with ZORYVE but also with the pipeline, considering Rob's experience. Really looking forward to collaborating with him once more.

Seamus Fernandez analyst
#10

Nice work. Congratulations. I'll get back in line.

Tyler Van Buren analyst
#11

Hi, everyone. Thanks, and congratulations on that strong sequential performance. A few things. First, would it be fair to anticipate ZORYVE franchise sales growing from Q2 to Q3 at a rate comparable to what we just saw from Q1 to Q2? Regarding vitiligo, with data coming next quarter, essentially right away, could you share more on enrollment, what demand you're seeing at sites, and interest in a topical treatment option? In particular, which data points do you need in order to proceed with this program and put more investment behind it?

Frank Watanabe executive
#12

Absolutely. Latha, would you like to handle the first one, and maybe Patrick, can you address the vitiligo question?

Latha Vairavan executive
#13

Yes, I'll accept that. My apologies—I needed to switch off mute. Hi, Tyler. I appreciate you asking. In terms of our net sales, we anticipate ongoing sequential expansion each quarter. I'd caution against tying your expectations to whatever run rate we're currently seeing on a quarterly basis. Instead, I think your focus should be on the initiatives we laid out, along with the guidance we provided and our expectations for what will occur this quarter. That should let you work out for yourself what the back half of the year will look like. I'm not going to hand you the growth rate answer directly—we do anticipate net sales rising from one quarter to the next, Q3 compared with Q2, and obviously, as a matter of course, Q4 compared with Q3. As Frank mentioned, we're going to somewhat temper the gross net improvements, meaning volume and demand will drive everything.

Patrick Burnett executive
#14

I'll take the vitiligo study. The vitiligo trial, as we said, has completed enrollment. The speed at which we enrolled was something we felt very good about. Bear in mind those were pediatric patients too, and that group is often harder to sign up. I believe that's a promising sign should a future vitiligo program come together. Regarding what we're seeking, OPZELURA has truly established the benchmark for a branded nonsteroidal in vitiligo. We see plenty of opportunity to compete there, correct? In this category there is basically just one additional drug. In certain respects we believe our product profile is genuinely better; we're referring to dosing once a day, being eligible for adjunctive use; we expect some systemics will enter this space too, particularly for patients with more severe disease. We'd view that as an advantage. Plus no black box and the pricing; many of these same attributes are what make us highly competitive in AD and our other indications too. Even assuming we match on efficacy and how quickly it works, we truly believe we'll be very competitive here because of those factors. What we're truly hoping for is superiority on either one of these two axes, particularly regarding speed of onset. One reason to potentially believe that is the PDE4 mechanism of action, which is based on anti-inflammatory effects as well as possibly acting directly on melanocytes. Given that mechanism of action, we've actually observed some brisk responses thanks to having such a potent PDE4 inhibitor. The rate of effect is another area where we're optimistic, though naturally we'll need to see those results when we get to the readout at the end of the year.

Judah Frommer analyst
#15

Yes. Hello, everyone. Congratulations on the quarter. I appreciate your taking my questions. Could you possibly give us a bit more detail regarding some patterns in the share held by the branded topical nonsteroidal category, perhaps particularly on new-to-brand patterns you are observing? On a different note, I am just wondering about enrollment patterns for the 234 trial. Clearly, it is a crowded area, but it appears new mechanisms are sought after. I am just curious how enrollment is progressing there. Thank you.

Frank Watanabe executive
#16

Certainly. Thank you, Judah. When it comes to share patterns, ZORYVE remains the top branded nonsteroidal available, sitting at just under 50% market share. ZORYVE is the main product fueling the category's expansion. As we have mentioned previously, these are patients transitioning from topical steroids. My view is we have only begun to tap into this and, if anything, considering the conversations happening in dermatology, that pattern will probably speed up in the future. Regarding the new-to-brand data, from memory, I do not want to say something inaccurate. Those figures are not immediately available to me. Without question, ZORYVE is performing extremely well against the other branded nonsteroidals. We anticipate that will persist. As for enrollment patterns, Patrick, could you perhaps speak to that once more?

Patrick Burnett executive
#17

Yes, of course. Let me just restate that with regard to 234, we are finishing up the healthy volunteer portion of the single ascending dose. There are two cohorts in the single dose that are in atopic dermatitis patients, but otherwise healthy patients who also have atopic dermatitis; we're transitioning into those AD cohorts. We will also be starting enrollment for the first multiple ascending dose. All of those are in atopic dermatitis patients. So far we have no experience in this trial with enrolling atopic dermatitis patients. I share your view that, particularly given that OX40 has left the pipeline and the competitive landscape here for atopic dermatitis patients, a new mechanism of action is something that will be very helpful for our recruitment. I believe this particular mechanism is one that will generate a great deal of interest. It is a competitive space. There is a lot happening. I think we are well-positioned to recruit these trials. Thank you.

Uy Ear analyst
#18

Hi, everyone. We appreciate you answering our query. Perhaps you could give us some clarity regarding the shift in gross net. I simply want to confirm that we heard you right.

Frank Watanabe executive
#19

Pardon me, would you mind repeating that? I missed what you asked.

Uy Ear analyst
#20

I was hoping you could give us some clarity on how gross net will shift as we move from this quarter into Q3 and Q4. My understanding is that during the first quarter, you indicated gross net would reach the low 50s by the time the year wraps up. Does that guidance still hold, or has it become more stable at this point? For my second question, would you mind going into a bit more detail about the launch of the PD-L1 study, the side effect study? What timeline do you have for its completion? Will there be a go-to decision to advance into phase III, or is this the kind of study where you can publish and leverage the data to support adoption? Thanks.

Frank Watanabe executive
#21

Okay. All right. Thanks. Yeah. Latha, would you like to address the gross net question regarding our outlook on gross net for the remainder of the year? Patrick, could you expand a little more on the PD-L1 study?

Latha Vairavan executive
#22

Yes. Hello, Uy. Throughout the year, we anticipate the gross net will remain within the 50s, then gradually decline into the low 50s, just as we previously stated. Our view is simply that the pace of gains will ease. Our starting point sat below where it was a year ago, despite being in the higher 50s. Your calculations will certainly reveal the gain we saw during Q2. Q3 and Q4 should bring some further improvement, though not as much as a year ago, and it will ultimately settle in the low 50s.

Uy Ear analyst
#23

All right. Appreciate that. That helped.

Patrick Burnett executive
#24

Yeah. To provide a bit more background on this trial, I believe your question gets right to the heart of figuring out what our goal is here. We honestly don't view this as a complete development program, necessarily. It's more a means of generating some information that could prove useful in making sure patients are able to get this, since some data will be published and made available, offering them an alternative. Many of these individuals go straight to topical steroids as their initial treatment, and they might require those for a large number of years. Having extra data for this group of patients, I think, so they can avoid having to give up on a therapy that typically works for them — it's really about publication, securing access, and not necessarily a complete development program. As for when the study will happen, we'll clearly keep you informed as things move forward, but it's only beginning at this point.

Uy Ear analyst
#25

Okay. Thanks.

Matt Barcus analyst
#26

Hey, good afternoon, and congratulations on the quarter. This is Matt Barcus, filling in for Andrew Tsai at Jefferies. I wanted to follow up regarding the updated guidance. Could you speak at a fundamental level about a few of the push-pulls underlying the ongoing growth and acceleration? Do you know of any additional investigator-sponsored or independent studies involving ZORYVE that might be launching during the coming year? If yes, could you discuss the market opportunities for each of those indications?

Frank Watanabe executive
#27

Thanks for that question, Matt. On the first one, my view is that during the back half of the year, prescription growth will serve as the main growth engine. As Latha said a moment ago, we do anticipate some gross-to-net improvement in Q3 and Q4, though likely more modest than what occurred in Q1 and Q2, and it won't be the principal growth driver. That demand increase will probably reflect a mix of the momentum already built plus the effect of several commercial demand drivers we've introduced, such as the sales force expansion, our ongoing DTC work, and the virtual health platform we announced recently. Each of these is genuinely working together to keep driving ZORYVE prescription growth. On your second question about IITs, at Arcutis we don't really fund many investigator-initiated trials. To be honest, the IIT process is rather clunky, and we prefer doing what are called collaborative research studies, in which the company can collaborate with the investigators. Several studies we referenced—the vitiligo trial, the HS trials, the nail psoriasis trial, and the PD-L1 trial Patrick mentioned a moment ago—are all collaborative research studies. As I said earlier in my remarks, we keep looking at other opportunities and other possible indications, and I believe we'll likely begin at least one additional proof of concept study this year for a different indication. Possibly more. With 47 diseases having some efficacy data, we probably have more options than resources. We won't chase every one of them either. I do expect you'll likely see one or more begin this year, and we may very well launch some further studies next year too. These give us highly cost- and time-efficient ways to evaluate a possible indication and then let us make a well-informed choice about whether to actually move forward with a large registrational study for that indication. Patrick, I don't know—is there anything else you'd like to add on that point?

Patrick Burnett executive
#28

No, I think that covers it, Frank. Thanks.

Matt Barcus analyst
#29

Thanks, I appreciate that.

Serge Belanger analyst
#30

Hello, and good afternoon — congratulations on a solid quarter. I have a few initial questions about the virtual health platform offering. Is the intention to reach a patient group that differs from the one you can currently access, and can you bring patients onto this platform through DTC efforts?

Frank Watanabe executive
#31

Yes.

Serge Belanger analyst
#32

Secondly-

Frank Watanabe executive
#33

Okay.

Serge Belanger analyst
#34

Go ahead.

Frank Watanabe executive
#35

No, that's all right. Go ahead.

Serge Belanger analyst
#36

I wanted to ask — I think I saw that you got a few new patents. I'm hoping that came from your press release and not some other one I looked at within the last hour. I'm just wondering how it strengthens the ZORYVE patent portfolio, and are those new patents something that could be listed in the Orange Book?

Frank Watanabe executive
#37

Yeah. Okay. On your first question, yes, I do view it as a distinct group of patients, right? Most of the patients we're gaining at this point, really nearly all of them, right, are people who a dermatologist has already examined and who are returning for a refill or a yearly checkup, or quite often, they're flaring up since the therapy they're on isn't working and the physician wants to try something else for them. That's someone already inside the dermatology care system who can reach a dermatologist, since they have an appointment, right? What's great about the virtual health platform is that where I live, you wait six months to get in with a dermatologist. Even in an acute case — I had shingles some years back, and it would have been a month before a dermatologist could see me. When something urgent and acute comes up, you want to be seen that day or the next day, right? In much of the United States, that's simply not feasible, given how supply and demand for dermatology specialist care don't line up. There are also plenty of areas across the country with no dermatologists at all, right? For instance, Patrick and I were in Roswell, New Mexico a few years ago. Within 250 miles, there's no dermatologist. Those patients simply lack the option of seeing a dermatologist. Our view is that the virtual health platform will truly complement patients who already see a dermatologist by letting patients without access to one — whether because of scheduling or geography — see a dermatologist that same day. Yes, to what you asked earlier, we absolutely believe direct to consumer is a significant driver here. If you think about it, a patient watches an interview with Tori or Max Homa, who also has the disease, and they think, "Gee, I want to learn more about this." They can head straight to our website. There's a click right on the homepage. You click it, and it takes you directly into the platform where the dermatologist is, and the patient can book a visit with the dermatologist immediately. We see this as a meaningful widening of the opportunity for ZORYVE, especially, again, considering some of the peculiarities of dermatology in the U.S. On the new patents. There are two new patents covering — one is the formulation, and the other is method of use. It's hard to say with certainty, though chances are they qualify for Orange Book listing. Around every ZORYVE formulation, our patent position is really robust. At present, I believe we have 18 patents in the Orange Book. Our IP portfolio keeps getting stronger bit by bit. These particular ones aren't hugely distinct. The loss of exclusivity timelines—37 for the cream and 42 for the foam—remain unchanged; we're constantly seeking to reinforce that already solid IP portfolio, and these 2 patents simply stem from that wider push.

Serge Belanger analyst
#38

Understood. Thanks.

Douglas Tsao analyst
#39

Hello there. Good afternoon, and I appreciate you taking my questions. I want to build on what we discussed regarding the telehealth program. Frank, I'm interested in knowing the rate at which someone who completes an initial online intake ends up with a prescription for ZORYVE. Do patients still occasionally have to complete some sort of step, or have they generally already done that? Have you observed signs that patients might complete an initial intake, perhaps needing to try a TCS because of their plan, and then return to eventually receive a script for ZORYVE anyway?

Frank Watanabe executive
#40

Certainly. Yes, thank you, Douglas. That's an excellent question. We're still in the very early stages, correct? I believe we'll need to observe over time which types of patients enter the system, and what occurs. A few things come to mind. To begin, once more, at the point when the physician, when the dermatologist assesses the patient, that dermatologist is free to select any treatment for that patient; it clearly doesn't have to be ZORYVE, correct? In our view ZORYVE is an excellent option, though it doesn't have to be. Should the patient's condition fall outside one of our approved indications, they will clearly receive a different therapy too. A lot of patients are using a topical steroid or have previously used one. My expectation is that a large share of patients arriving on the telehealth platform will have previously used a topical steroid and are seeking a non-steroidal option. Perhaps they've heard, once more, Max or Stella or Tori describe their experiences and their frustrations. Perhaps they're worried about topical steroids because of what they've learned regarding topical steroid risks, and they wish to find an alternative. My sense is that a majority of patients coming in probably have already used a topical steroid. As I said, we have the infrastructure ready to deliver insurance and fulfillment assistance for these telehealth patients that stacks up very well against what they'd encounter at a dermatologist's office. We're truly focused on how we make this process more efficient, regardless of whether you're seeing a dermatologist face to face or seeing them via the internet. I think it's conceivable that certain patients might ultimately need to step through a different product if they're a new onset patient. Even under those circumstances, given the problems surrounding topical steroids, those patients will probably return before too long to obtain ZORYVE once they've satisfied the step requirement.

Douglas Tsao analyst
#41

All right, excellent. That is genuinely useful.

Tolani Uthman analyst
#42

Hello, everybody. Tolani Uthman here, filling in for Rich. Appreciate you fielding our questions. I'll start with one about the commercial side. When you consider rolling out the PCP and pediatric sales teams for ZORYVE over the next few months, what's your estimate of the number of patients who aren't being properly referred to dermatologists by PCPs and pediatricians? Put another way, roughly how many patients do you figure that new sales force could reach?

Frank Watanabe executive
#43

Sure. Yeah. Excellent question; we understand that roughly 50% of all patients suffering from psoriasis, AD, and seb derm never get seen by a dermatologist. Correct? The data establishes this quite firmly. Most of those individuals are instead visiting a primary care physician or a pediatrician; that excludes people who aren't presently receiving active treatment; we tend to set those patients aside since it's consistently hard to get patients outside the system engaged. Among patients who are currently on prescription therapy, roughly 50% are seen by non-dermatologists, with primary care and pediatricians making up the vast bulk; through this first sales force, we're reaching only a relatively modest portion of the primary care and pediatric community. As I noted during my prepared remarks before, our target is extremely high volume physicians inclined to pick up new therapies, and in certain instances, physicians who have already prescribed ZORYVE. We believe that's the place where we'll achieve the quickest early traction; after that, as we assess and refine our strategy, and develop an understanding of what return on investment the primary care initiative delivers, we'll determine the appropriate size for this primary care sales force and how deeply into primary care and pediatrics we should go. That could shift down the road, much like what happened with the dermatology sales team too. At the outset, our focus will be a modest slice of an enormous pie. One figure we provided during an earlier quarterly call is that the U.S. has somewhere around 500,000 primary care providers; that's an enormous figure; clearly, we aren't pursuing 500,000 providers. It works out that roughly 5% of those primary care physicians and pediatricians, meaning around 25,000 physicians, are responsible for one third of all topical prescriptions originating from primary care and pediatrics. There's an incredibly abundant seam of opportunity within the primary care and pediatric community among these highly concentrated, higher volume physicians, and that is genuinely where our initial efforts will be concentrated as we grow.

Tolani Uthman analyst
#44

Okay, that's really useful. Thank you. Then one more question, this time specifically about atopic dermatitis. In what way would a possible ZORYVE approval for infants — those aged three to 24 months — broaden that market opportunity? And what kind of pre-launch efforts, if any, are you folks doing to help drive strong uptake in that setting?

Frank Watanabe executive
#45

Yeah. We believe this is going to be a very significant catalyst. Roughly 1 million patients in that age bracket, the three to 24-month group, suffer from atopic dermatitis. That's a big market. As for what's approved today for three to 24-month-olds, there are six of the topical steroids cleared for that age group, EUCRISA is cleared for that age group, and that's all. Physicians either have to treat these infants off-label, or they must resort to one of those seven drugs that carries approval. I think that is truly the reason we're seeing so much enthusiasm, particularly from the pediatric dermatology community, since their options are so limited. Their options aren't good ones, above all the non-steroidal choices; every one of them has already used ZORYVE, they're aware of how good it is, and they're extremely eager to be able to use it in this very young population. Patrick can address this as well, but there are worries about steroids for any patient, yet those worries are especially severe in this 3 to 24-month population. Honestly, no parent wants to put their child on steroids, correct? If we can provide a genuinely effective, very safe, and well-tolerated non-steroidal choice for treating those patients, we believe we'll see very, very meaningful uptake in that population. Patrick, is there anything you'd like to add to that?

Patrick Burnett executive
#46

Sure, I agree with you completely. A reluctance to use steroids like that creates genuine difficulties, and I think pediatric dermatology is where you can see that most clearly. Frank, you were recently at the Society for Pediatric Dermatology meeting. If we look back even to last year, when we attended, there was already significant awareness of the study that was underway—this was before the data existed—and people wanted to get it to their patients, given how few treatment choices Frank described. With the data now available and already presented at the AAD, the work our medical affairs team is doing largely involves responding to the many inquiries and the strong interest regarding what our data demonstrate. How does this compare with or differ from what we have for patients aged two and older, especially when it comes to atopic dermatitis? We're mainly ensuring that all questions get addressed as we get ready and work toward launching at the start of next year.

Tolani Uthman analyst
#47

That tracks. Thanks so much.

Frank Watanabe executive
#48

Just ahead of wrapping up — this really is a live session we're running. Serge, I've got something for the question you raised, plus one thing to fix. What I said earlier wasn't right: the count on ZORYVE is 28 patents, not 18. Mas, who serves as our general counsel, set me straight, and he verified that these two additional patents can likewise be listed in the Orange Book. I felt it was worth making that clear. Right. Well, that's yet another strong quarter. I'm genuinely grateful to each of you for dialing in today. I realize this stretch of the year is extremely hectic, with everybody reporting quarterly numbers, so thank you for your time and focus and for all the excellent questions — and we can't wait to speak with all of you once more on the Q3 call. Thanks. Bye-bye.

Operator operator
#49

This concludes today's conference call. Thank you for participating, and you may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Arcutis Biotherapeutics, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Arcutis Biotherapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.